碘对比剂肾损伤的检测方法

发布时间：2018-06-15 22:46

本文选题：肾病 + 对比剂　；参考：《放射学实践》2017年06期

【摘要】：对比剂肾病是碘对比剂注射后严重的并发症,对其早期及时检测及评价具有重要临床意义。病理诊断虽然可作为诊断肾脏损伤的金标准,但其有创性及次数限制也使其在临床应用有很大局限。目前临床上主要通过测量患者的Scr水平和GFR来判断肾功能,但肌酐变异较大,且对肾功能改变的反应较为滞后。中性粒细胞明胶酶相关载脂蛋白(NGAL)及胱抑制素C(CysC)在肾脏损伤后较早出现升高,已被视为现在已知最可靠的早期预测CIN的生化标志物之一。肾脏功能磁共振(fMRI)无创、无辐射,可重复性与接受性强,对对比剂肾病的早期诊断、指导治疗、判断预后都有较高的价值。本文旨在总结目前临床上对比剂肾病的不同检测方法,为临床选择更恰当的评估对比剂肾损害的方法提供依据。
[Abstract]:Contrast nephropathy is a serious complication after iodine contrast injection, which has important clinical significance for early and timely detection and evaluation. Although pathological diagnosis can be used as a gold standard for the diagnosis of renal injury, its invasiveness and limitation of times also limit its clinical application. At present, renal function is mainly judged by measuring SCR level and GFR, but creatinine varies greatly, and the response to renal function change is lagged. Neutrophil gelatinase-associated apolipoprotein NGALs (ANGALs) and cystatin Cy CysC (cystatin C) rise early after renal injury and have been regarded as one of the most reliable biochemical markers for predicting cin in the early stage. Renal functional magnetic resonance imaging (fMRI) is noninvasive, radiation-free, reproducible and receptive. It is of great value in early diagnosis, guidance of treatment and prognosis of contrast-agent nephropathy. The purpose of this paper is to summarize the different methods of detecting contrast-agent nephropathy in clinic, and to provide evidence for clinical evaluation of renal damage with contrast agent.
【作者单位】：中国医科大学附属第一医院放射线科;
【基金】：国家科学自然基金面上项目(81571635) 沈阳市科学技术项目计划(F15-199-1-39)
【分类号】：R445.2;R692

【相似文献】